Bipartisan bill on follow-on biologics unveiled in Congress

03/11/2009 | Reuters · Google

Reps. Henry Waxman, D-Calif., and Nathan Deal, R-Ga., on Wednesday introduced a proposal that would allow the FDA to approve follow-on biologics. The bill would give brand-name biotech drugs three to five years of market exclusivity, shorter than the 14 years requested by biotech companies. The legislation would lead to a path that "jeopardizes the continued development of new breakthrough therapies and potential cures for debilitating diseases," BIO President Jim Greenwood said.

View Full Article in:

Reuters · Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN